La cadena de opciones muestra datos clave de las opciones de acciones de Trinity Biotech a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Trinity Biotech..

Trinity Biotech (NASDAQ:TRIB) Bolsa, Cadena de Opciones

Trinity Biotech

Trinity Biotech PLC is in the business of developing, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point-of-care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Immublot, and others. Geographically, it has two segments namely the Americas, and the Rest of World - Ireland from which it derives a majority of its revenue from the Americas segment.

Trinity Biotech plc - American Depositary Shares

Trinity Biotech PLC

Tribe - United States Dollar

XINDA INTL CORP by Xinda International Corp.

Tribal Rides International Corp

TRIBE PPTY TECHNOLOGIES by Tribe Property Technologies Inc.

Tribe Property Technologies Inc

Tribeca Resources Corp

News

Guidance

TRIB

Trinity Biotech Reiterates Guidance To Achieve 2024 Sales Revenue For TrinScreen HIV Of Approximately $10M

Trinity Biotech Reiterates Guidance To Achieve $20M Of Annualized Run-rate EBITDASO On Annualized Run-rate Revenues Of $75M By Q2 2025

Trinity Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIB#NASDAQ">TRIB</a>) reported quarterly losses of $(0.46) per ADS which beat the analyst consensus estimate of $(0.54) by 14.81 percent. This is a 47.73 percent increase over losses of $(0.88) per ADS from the same period last year. The company reported quarterly sales of $15.15 million which missed the analyst consensus estimate of $16.50 million by 8.17 percent. This is a 3.24 percent increase over sales of $14.68 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

Trinity Biotech Q3 2024 GAAP EPADS $(0.46) Beats $(0.54) Estimate, Sales $15.15M Miss $16.50M Estimate

<h3>Companies Reporting Before The Bell</h3>
• Sigma Lithium (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGML#NASDAQ">SGML</a>) is projected to report quarterly earnings at $0.09 per share on revenue of $72.08 million. 
• Trinity Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIB#NASDAQ">TRIB</a>) is projected to report quarterly loss at $0.54 per share on revenue of $16.50 million. 
• Digihost Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DGHI#NASDAQ">DGHI</a>) is projected to report quarterly loss at $0.13 per share on revenue of $9.90 million. 
• Aegon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEG#NYSE">AEG</a>) is projected to report earnings for its third quarter. 
• Bio-Path Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPTH#NASDAQ">BPTH</a>) is expected to report earnings for its third quarter. 
• WiSA Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WISA#NASDAQ">WISA</a>) is likely to report quarterly loss at $0.68 per share on revenue of $1.00 million. 
• AIM ImmunoTech (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AIM#AMEX">AIM</a>) is likely to report quarterly loss at $0.10 per share on revenue of $20 thousand. 
• Nexxen International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEXN#NASDAQ">NEXN</a>) is likely to report quarterly earnings at $0.10 per share on revenue of $87.84 million. 
• RLX Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RLX#NYSE">RLX</a>) is expected to report quarterly earnings at $0.03 per share on revenue of $105.08 million. 
• Alibaba Gr Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) is projected to report quarterly earnings at $2.10 per share on revenue of $33.95 billion. 
• Spectrum Brands Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPB#NYSE">SPB</a>) is estimated to report quarterly earnings at $1.02 per share on revenue of $746.54 million. 
<h3>Companies Reporting After The Bell</h3>
• Neurogene (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NGNE#NASDAQ">NGNE</a>) is likely to report earnings for its third quarter. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BABA

BPTH

DGHI

NEXN

NGNE

SGML

WISA

Earnings Scheduled For November 15, 2024

Trinity Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIB#NASDAQ">TRIB</a>) will release its quarterly earnings report on Friday, 2024-11-15. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Trinity Biotech to report an earnings per share (EPS) of $-0.54.
The market awaits Trinity Biotech's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
Here's a look at Trinity Biotech's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td></td>
<td></td>
<td>-0.60</td>
<td>-0.75</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.71</td>
<td>-0.37</td>
<td>-0.72</td>
<td>-0.88</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-9.0%</td>
<td>4.0%</td>
<td>-1.0%</td>
<td>-4.0%</td>
</tr>
</tbody>
</table>

<h3>Performance of Trinity Biotech Shares</h3>
Shares of Trinity Biotech were trading at $1.55 as of November 12. Over the last 52-week period, shares are down 18.95%. Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. 
<a href="https://www.benzinga.com/quote/TRIB/earnings">To track all earnings releases for Trinity Biotech visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insights Ahead: Trinity Biotech's Quarterly Earnings

Trinity Biotech Regains Nasdaq Compliance With Minimum Market Value Requirement

<h3>Gainers</h3>
<ul>
<li>Envoy Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COCH#NASDAQ">COCH</a>) shares increased by 66.0% to $4.4 during Friday's pre-market session. The company's market cap stands at $86.8 million. </li>
<li>Theriva Biologics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/TOVX#AMEX">TOVX</a>) stock rose 43.83% to $2.1. The market value of their outstanding shares is at $2.8 million. </li>
<li>Athira Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATHA#NASDAQ">ATHA</a>) shares rose 26.13% to $0.54. The market value of their outstanding shares is at $20.6 million. </li>
<li>Pro-Dex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDEX#NASDAQ">PDEX</a>) shares increased by 18.06% to $36.62. The company's market cap stands at $122.9 million. As per the news, the Q1 earnings report came out yesterday. </li>
<li>Molecular Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOLN#NASDAQ">MOLN</a>) shares rose 16.79% to $6.26. The market value of their outstanding shares is at $230.5 million. </li>
<li>ChromaDex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXC#NASDAQ">CDXC</a>) stock moved upwards by 16.04% to $4.05. The market value of their outstanding shares is at $307.5 million. As per the news, the Q3 earnings report came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Lexicon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXRX#NASDAQ">LXRX</a>) shares fell 39.5% to $1.18 during Friday's pre-market session. The market value of their outstanding shares is at $426.5 million. </li>
<li>OneMedNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONMD#NASDAQ">ONMD</a>) stock declined by 10.37% to $0.77. The company's market cap stands at $18.3 million. </li>
<li>Biofrontera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BFRI#NASDAQ">BFRI</a>) shares decreased by 9.76% to $1.11. The company's market cap stands at $6.1 million. </li>
<li>Trinity Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIB#NASDAQ">TRIB</a>) stock declined by 9.1% to $1.6. The company's market cap stands at $15.1 million. </li>
<li>bioAffinity Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIAF#NASDAQ">BIAF</a>) stock fell 9.1% to $1.3. The market value of their outstanding shares is at $20.1 million. </li>
<li>Matinas BioPharma Hldgs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MTNB#AMEX">MTNB</a>) shares decreased by 8.07% to $0.57. The market value of their outstanding shares is at $2.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ATHA

BFRI

BIAF

CDXC

Envoy Medical, Inc. - Class A Common Stock

COCH

LXRX

MOLN

MTNB

ONMD

PDEX

TOVX

12 Health Care Stocks Moving In Friday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Envoy Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COCH#NASDAQ">COCH</a>) stock moved upwards by 66.0% to $4.4 during Friday's pre-market session. The market value of their outstanding shares is at $86.8 million. </li>
<li>Theriva Biologics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/TOVX#AMEX">TOVX</a>) shares increased by 43.83% to $2.1. The company's market cap stands at $2.8 million. </li>
<li>Athira Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATHA#NASDAQ">ATHA</a>) stock increased by 26.13% to $0.54. The company's market cap stands at $20.6 million. </li>
<li>Pro-Dex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDEX#NASDAQ">PDEX</a>) stock moved upwards by 18.06% to $36.62. The market value of their outstanding shares is at $122.9 million. As per the news, the Q1 earnings report came out yesterday. </li>
<li>Molecular Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOLN#NASDAQ">MOLN</a>) stock rose 16.79% to $6.26. The company's market cap stands at $230.5 million. </li>
<li>ChromaDex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXC#NASDAQ">CDXC</a>) shares increased by 16.04% to $4.05. The company's market cap stands at $307.5 million. As per the news, the Q3 earnings report came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Lexicon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXRX#NASDAQ">LXRX</a>) stock decreased by 39.5% to $1.18 during Friday's pre-market session. The market value of their outstanding shares is at $426.5 million. </li>
<li>OneMedNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONMD#NASDAQ">ONMD</a>) stock decreased by 10.37% to $0.77. The market value of their outstanding shares is at $18.3 million. </li>
<li>Biofrontera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BFRI#NASDAQ">BFRI</a>) shares declined by 9.76% to $1.11. The market value of their outstanding shares is at $6.1 million. </li>
<li>Trinity Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIB#NASDAQ">TRIB</a>) shares fell 9.1% to $1.6. The company's market cap stands at $15.1 million. </li>
<li>bioAffinity Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIAF#NASDAQ">BIAF</a>) stock fell 9.1% to $1.3. The market value of their outstanding shares is at $20.1 million. </li>
<li>Matinas BioPharma Hldgs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MTNB#AMEX">MTNB</a>) stock declined by 8.07% to $0.57. The company's market cap stands at $2.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

<h3>Gainers</h3>
<ul>
<li>Athira Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATHA#NASDAQ">ATHA</a>) stock rose 28.5% to $0.55 during Thursday's after-market session. The market value of their outstanding shares is at $21.0 million. </li>
<li>Theriva Biologics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/TOVX#AMEX">TOVX</a>) shares increased by 28.08% to $1.87. The company's market cap stands at $2.5 million. </li>
<li>Pro-Dex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDEX#NASDAQ">PDEX</a>) shares increased by 19.69% to $37.13. The market value of their outstanding shares is at $124.6 million. </li>
<li>ChromaDex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXC#NASDAQ">CDXC</a>) stock increased by 18.62% to $4.14. The market value of their outstanding shares is at $314.3 million. As per the news, the Q3 earnings report came out today. </li>
<li>Halozyme Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HALO#NASDAQ">HALO</a>) stock moved upwards by 7.7% to $54.49. The company's market cap stands at $6.9 billion. The company's, Q3 earnings came out today. </li>
<li>Ardelyx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARDX#NASDAQ">ARDX</a>) shares rose 7.49% to $6.31. The company's market cap stands at $1.4 billion. The company's, Q3 earnings came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Biofrontera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BFRI#NASDAQ">BFRI</a>) stock decreased by 10.6% to $1.1 during Thursday's after-market session. The company's market cap stands at $6.0 million. </li>
<li>BioRestorative Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRTX#NASDAQ">BRTX</a>) stock decreased by 5.74% to $1.47. The market value of their outstanding shares is at $10.1 million. </li>
<li>Palisade Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PALI#NASDAQ">PALI</a>) stock decreased by 5.52% to $2.57. The company's market cap stands at $3.0 million. </li>
<li>Innovative Eyewear (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUCY#NASDAQ">LUCY</a>) shares fell 5.49% to $7.75. The company's market cap stands at $18.6 million. </li>
<li>Ocean Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCEA#NASDAQ">OCEA</a>) shares fell 5.23% to $0.83. The company's market cap stands at $28.8 million. </li>
<li>Trinity Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIB#NASDAQ">TRIB</a>) stock decreased by 5.12% to $1.67. The market value of their outstanding shares is at $15.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ARDX

BRTX

HALO

LUCY

OCEA

PALI

12 Health Care Stocks Moving In Thursday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>GlycoMimetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLYC#NASDAQ">GLYC</a>) stock rose 147.9% to $0.42 during Tuesday's pre-market session. The market value of their outstanding shares is at $26.8 million. </li>
<li>Shuttle Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHPH#NASDAQ">SHPH</a>) stock rose 56.39% to $2.08. The market value of their outstanding shares is at $6.1 million. </li>
<li>Lixte Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIXT#NASDAQ">LIXT</a>) shares moved upwards by 55.73% to $2.04. The market value of their outstanding shares is at $4.5 million. </li>
<li>NovaBay Pharmaceuticals (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NBY#AMEX">NBY</a>) stock increased by 52.83% to $0.84. The company's market cap stands at $4.1 million. </li>
<li>Immuron (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMRN#NASDAQ">IMRN</a>) stock increased by 29.53% to $2.5. The market value of their outstanding shares is at $14.2 million. </li>
<li>Protagenic Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIX#NASDAQ">PTIX</a>) stock increased by 22.44% to $0.69. The market value of their outstanding shares is at $3.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>TransMedics Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMDX#NASDAQ">TMDX</a>) stock declined by 23.6% to $96.46 during Tuesday's pre-market session. The market value of their outstanding shares is at $3.2 billion. As per the press release, Q3 earnings came out yesterday. </li>
<li>Cardio Diagnostics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDIO#NASDAQ">CDIO</a>) stock declined by 19.18% to $0.25. The market value of their outstanding shares is at $7.7 million. </li>
<li>Biora Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIOR#NASDAQ">BIOR</a>) stock decreased by 16.97% to $3.67. The company's market cap stands at $13.4 million. </li>
<li>Trinity Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIB#NASDAQ">TRIB</a>) shares decreased by 15.01% to $1.87. The company's market cap stands at $17.7 million. </li>
<li>American Well (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMWL#NYSE">AMWL</a>) stock decreased by 14.41% to $8.5. The company's market cap stands at $127.4 million. </li>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) shares fell 13.08% to $1.13. The market value of their outstanding shares is at $6.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AMWL

BIOR

Cardio Diagnostics Holdings Inc. - Common stock

CDIO

GLYC

HCTI

IMRN

LIXT

PTIX

SHPH

TMDX

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>GlycoMimetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLYC#NASDAQ">GLYC</a>) shares increased by 147.9% to $0.42 during Tuesday's pre-market session. The company's market cap stands at $26.8 million. </li>
<li>Shuttle Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHPH#NASDAQ">SHPH</a>) stock moved upwards by 56.39% to $2.08. The market value of their outstanding shares is at $6.1 million. </li>
<li>Lixte Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIXT#NASDAQ">LIXT</a>) stock rose 55.73% to $2.04. The company's market cap stands at $4.5 million. </li>
<li>NovaBay Pharmaceuticals (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NBY#AMEX">NBY</a>) stock rose 52.83% to $0.84. The market value of their outstanding shares is at $4.1 million. </li>
<li>Immuron (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMRN#NASDAQ">IMRN</a>) shares moved upwards by 29.53% to $2.5. The company's market cap stands at $14.2 million. </li>
<li>Protagenic Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIX#NASDAQ">PTIX</a>) shares rose 22.44% to $0.69. The market value of their outstanding shares is at $3.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>TransMedics Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMDX#NASDAQ">TMDX</a>) shares declined by 23.6% to $96.46 during Tuesday's pre-market session. The market value of their outstanding shares is at $3.2 billion. As per the news, the Q3 earnings report came out yesterday. </li>
<li>Cardio Diagnostics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDIO#NASDAQ">CDIO</a>) shares declined by 19.18% to $0.25. The company's market cap stands at $7.7 million. </li>
<li>Biora Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIOR#NASDAQ">BIOR</a>) shares decreased by 16.97% to $3.67. The company's market cap stands at $13.4 million. </li>
<li>Trinity Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIB#NASDAQ">TRIB</a>) stock fell 15.01% to $1.87. The company's market cap stands at $17.7 million. </li>
<li>American Well (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMWL#NYSE">AMWL</a>) shares fell 14.41% to $8.5. The market value of their outstanding shares is at $127.4 million. </li>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) shares fell 13.08% to $1.13. The company's market cap stands at $6.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

WIIM

Trinity Biotech shares are trading higher after the company announced the acquisition of EpiCapture. Also, the company announced a strategic investment in Novus Diagnostics to advance development and commercialization of Novus' point-of-care diagnostic solutions.

Trinity Biotech plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIB#NASDAQ">TRIB</a>), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced the acquisition of EpiCapture Limited, a company developing a non-invasive test for monitoring the risk of aggressive prostate cancer. This acquisition marks Trinity Biotech's strategic expansion into the oncology diagnostics market.
Prostate cancer is the most common non-skin cancer among men in the U.S., with about 1 in 8 men diagnosed during their lifetime and the cost for diagnosis and treatment estimated at over approximately $10 billion annually. The ability to accurately monitor prostate cancer progression is critical, as the disease can often be slow-growing, and unnecessary invasive interventions, such as prostate biopsies, can lead to significant complications. The EpiCapture test could significantly reduce the frequency of these interventions, thereby improving the quality of life for patients.
&nbsp;
Trinity Biotech acquired EpiCapture for initial consideration of approximately $3 million, with an additional consideration of $0.5 million contingent on the achievement of future milestones. The initial consideration was paid through the issuance of approximately 1.7 million American Depository Shares (ADS) in Trinity Biotech.
EpiCapture is a spin-out company of NovaUCD, part of University College Dublin.

Trinity Biotech Announces Acquisition Of Prostate Cancer Focused EpiCapture For Initial Consideration Of ~$3M, With An Additional Consideration Of $0.5M Contingent On The Achievement Of Future Milestones

Biotech

General

Trinity Biotech Has Acquired A 12.5% Equity Stake In Novus Diagnostics, Valued At ~$2.5M To Boost Development Of Rapid 15-Minute Sepsis Testing Platform; Aims To Transform Sepsis Diagnosis And Improve Patient Outcomes

<h3>Gainers</h3>
<ul>
<li>Tevogen Bio Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVGN#NASDAQ">TVGN</a>) stock moved upwards by 202.6% to $1.15 during Monday's regular session. The market value of their outstanding shares is at $196.0 million. </li>
<li>INVO Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INVO#NASDAQ">INVO</a>) stock moved upwards by 55.72% to $1.02. The market value of their outstanding shares is at $3.9 million. </li>
<li>Longboard Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LBPH#NASDAQ">LBPH</a>) stock moved upwards by 51.16% to $58.8. The company's market cap stands at $2.2 billion. </li>
<li>Rani Therapeutics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RANI#NASDAQ">RANI</a>) stock moved upwards by 36.13% to $2.75. The market value of their outstanding shares is at $80.5 million. </li>
<li>Inventiva (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVA#NASDAQ">IVA</a>) stock moved upwards by 32.27% to $2.5. The company's market cap stands at $130.9 million. </li>
<li>Gritstone Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRTS#NASDAQ">GRTS</a>) shares moved upwards by 29.46% to $0.07. The market value of their outstanding shares is at $7.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Molecular Templates (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTEM#NASDAQ">MTEM</a>) stock declined by 74.8% to $0.37 during Monday's regular session. The company's market cap stands at $2.4 million. </li>
<li>Trinity Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIB#NASDAQ">TRIB</a>) shares decreased by 18.75% to $1.62. The company's market cap stands at $15.3 million. </li>
<li>Virpax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRPX#NASDAQ">VRPX</a>) stock decreased by 18.24% to $0.39. The market value of their outstanding shares is at $1.8 million. </li>
<li>Nuwellis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUWE#NASDAQ">NUWE</a>) shares declined by 15.92% to $1.4. The market value of their outstanding shares is at $2.6 million. </li>
<li>Impact BioMedical (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBO#AMEX">IBO</a>) stock decreased by 14.2% to $1.33. The market value of their outstanding shares is at $15.2 million. </li>
<li>Mainz Biomed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYNZ#NASDAQ">MYNZ</a>) shares decreased by 12.19% to $0.29. The company's market cap stands at $6.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

GRTS

INVO

LBPH

MTEM

MYNZ

NUWE

RANI

TVGN

VRPX

12 Health Care Stocks Moving In Monday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>Tevogen Bio Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVGN#NASDAQ">TVGN</a>) stock rose 31.2% to $0.34 during Wednesday's after-market session. The market value of their outstanding shares is at $58.0 million. </li>
<li>MSP Recovery (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIFW#NASDAQ">LIFW</a>) stock moved upwards by 9.44% to $0.15. The company's market cap stands at $3.9 million. </li>
<li>TC BioPharm (Holdings) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCBP#NASDAQ">TCBP</a>) shares moved upwards by 7.42% to $5.35. The company's market cap stands at $2.7 million. </li>
<li>Bionano Genomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNGO#NASDAQ">BNGO</a>) shares moved upwards by 4.99% to $0.44. The market value of their outstanding shares is at $37.9 million. </li>
<li>Jasper Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JSPR#NASDAQ">JSPR</a>) shares rose 4.96% to $15.85. The company's market cap stands at $239.4 million. </li>
<li>Akoya Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKYA#NASDAQ">AKYA</a>) stock increased by 4.95% to $3.18. The company's market cap stands at $157.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>10x Genomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXG#NASDAQ">TXG</a>) stock decreased by 25.6% to $15.5 during Wednesday's after-market session. The company's market cap stands at $1.8 billion. </li>
<li>Trinity Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIB#NASDAQ">TRIB</a>) shares declined by 6.98% to $1.6. The company's market cap stands at $15.1 million. </li>
<li>CERo Therapeutics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERO#NASDAQ">CERO</a>) stock declined by 6.55% to $0.1. The company's market cap stands at $5.1 million. </li>
<li>Carmell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTCX#NASDAQ">CTCX</a>) shares fell 6.35% to $0.4. The company's market cap stands at $8.3 million. </li>
<li>Nuwellis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUWE#NASDAQ">NUWE</a>) stock decreased by 6.29% to $1.49. The company's market cap stands at $2.7 million. </li>
<li>Akanda (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKAN#NASDAQ">AKAN</a>) stock decreased by 5.51% to $1.03. The market value of their outstanding shares is at $2.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AKAN

AKYA

BNGO

CERO

CTCX

Jasper Therapeutics, Inc. - Class A Common Stock

JSPR

LIFW

TCBP

12 Health Care Stocks Moving In Wednesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Ontrak (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OTRK#NASDAQ">OTRK</a>) shares rose 63.7% to $2.98 during Tuesday's pre-market session. The company's market cap stands at $9.5 million. </li>
<li>Bio-Path Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPTH#NASDAQ">BPTH</a>) stock rose 51.53% to $1.29. The market value of their outstanding shares is at $3.2 million. </li>
<li>Virios Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIRI#NASDAQ">VIRI</a>) stock increased by 34.8% to $0.19. The company's market cap stands at $5.1 million. </li>
<li>ZimVie (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZIMV#NASDAQ">ZIMV</a>) shares moved upwards by 15.35% to $17.8. The market value of their outstanding shares is at $490.7 million. </li>
<li>GRI Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRI#NASDAQ">GRI</a>) stock increased by 15.18% to $0.4. The market value of their outstanding shares is at $1.1 million. </li>
<li>Entero Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTO#NASDAQ">ENTO</a>) shares rose 12.17% to $0.58. The market value of their outstanding shares is at $1.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Vincerx Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VINC#NASDAQ">VINC</a>) stock decreased by 15.5% to $0.59 during Tuesday's pre-market session. The market value of their outstanding shares is at $18.2 million. </li>
<li>Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) stock fell 11.57% to $5.94. The company's market cap stands at $362.7 million. </li>
<li>LogicMark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGMK#NASDAQ">LGMK</a>) stock decreased by 10.64% to $0.12. The market value of their outstanding shares is at $1.4 million. </li>
<li>TransCode Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAZ#NASDAQ">RNAZ</a>) shares fell 9.59% to $0.49. The market value of their outstanding shares is at $8.4 million. </li>
<li>Tevogen Bio Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVGN#NASDAQ">TVGN</a>) shares declined by 9.24% to $0.29. The market value of their outstanding shares is at $49.4 million. </li>
<li>Trinity Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIB#NASDAQ">TRIB</a>) stock fell 8.83% to $1.24. The company's market cap stands at $11.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ENTO

ALPS ETF Trusthen & Steers Global Realty Majors ETF

LGMK

OTRK

RNAZ

SAGE

VINC

VIRI

ZIMV

Trinity Biotech shares are trading higher after the company announced it completed its first pre-pivotal clinical trial in Europe for its continuous glucose monitor technology.

New Factory-Calibrated CGM Achieves High Accuracy With Modular Design To Enhance User Experience And Reduce Costs; Results To Guide Further Sensor Design Optimizations

Trinity Biotech Reports Pre-Pivotal Trial Results For Next-Generation Continuous Glucose Monitor In Europe

-Metabolomics Diagnostics, a deep-tech machine learning diagnostic platform developer, has developed an innovative test, PrePsia, to accurately predict the risk of preeclampsia in pregnant women- &nbsp;
-The PrePsia test can predict preeclampsia risk as early as in the 12th week of pregnancy, allowing for early interventions to prevent serious health issues for mothers and their babies-
-PrepSia will be commercialized in the U.S. market in 2025 through Trinity Biotech's New York-based Immco reference laboratory-
DUBLIN, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIB#NASDAQ">TRIB</a>), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced that it has acquired privately held Metabolomics Diagnostics, an Irish deep-tech company, specialized in the development of novel biomarker-based diagnostic solutions for complex diseases. The deal values Metabolomics Diagnostics with an enterprise value of approximately $1.3 million with the consideration consisting of just over 270,000 Trinity Biotech plc's ADS with the balance of consideration being in cash and the assumption of liabilities.
This acquisition provides Trinity Biotech with a strategically important deep-tech platform of mass spectrometry combined with machine learning powered bioinformatics. Trinity Biotech will initially leverage its New York State-based Immco reference laboratory to rapidly commercialise the PrePsia test in the U.S. market, while examining the launch of this test in international markets. This technology platform represents another long-term growth driver alongside Trinity Biotech's continuous glucose monitoring (CGM) technology.

Trinity Biotech's Deal Values Metabolomics Diagnostics With An Enterprise Value Of ~$1.3M With The Consideration Consisting Of Just Over 270,000 Trinity Biotech's ADS With The Balance Of Consideration Being In Cash And The Assumption Of Liabilities

Trinity Biotech (TRIB) has released an update. Trinity Biotech has made a strategic investment of $2.5 million to acquire a 12.5% equity stake in N...

Trinity Biotech Invests in Rapid Sepsis Testing Innovation

Trinity Biotech (TRIB) has released an update. Trinity Biotech has strategically expanded into the oncology diagnostics market with the acquisition...

Trinity Biotech Acquires EpiCapture to Enter Oncology Market

Trinity Biotech regains compliance with Nasdaq

Trinity Biotech (TRIB) has released an update. Trinity Biotech has successfully regained compliance with Nasdaq's listing requirements, ensuring it...

Trinity Biotech Secures Nasdaq Compliance, Eyes Growth

Reports Q3 revenue $15.152M vs $14.677M last year Published first on TheFly – the ultimate source for real-time, market-moving breaking financial n...

Trinity Biotech reports Q3 EPS (46c) vs (88c) last year

Trinity Biotech Plc (TRIB) Q3 2024 Earnings Call Transcript

Trinity Biotech (TRIB) has released an update. Trinity Biotech reported a 3% increase in Q3 2024 revenue to $15.2 million, driven by strong demand ...

Trinity Biotech's Q3 2024 Revenue and Strategic Growth

Trinity Biotech files to sell 0.65M American Depositary shares by selling shareholders

17:03 EST Trinity Biotech (TRIB) files to sell 650,000 American Depositary Shares for holders Published first on TheFly – the ultimate source for r...

Trinity Biotech files to sell 650,000 American Depositary Shares for holders

Trinity Biotech ( ($TRIB) ) has released its Q3 earnings. Here is a breakdown of the information Trinity Biotech presented to its investors. Trinit...

Comments

Trinity Biotech

Trinity Biotech (TRIB) Opciones

Trinity Biotech (NASDAQ:TRIB) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL